Abstract 956P
Background
Microvascular invasion (MVI) is closely associated with high risk of recurrence and poor long-term survival in HCC patients. For these patients, active and effective adjuvant therapy is of great significance to improve the prognosis. Therefore, we explored the efficacy and safety of interferon-α (IFN-α) combined with PD-1 monoclonal antibody (tislelizumab, TIS) as adjuvant therapy for HCC patients with MVI.
Methods
In this phase 2 study, histologically confirmed HCC patients who had undergone curative resection with MVI, Child-Pugh A, and an ECOG PS ≤1 were enrolled. Patients separately received TIS (200 mg IV Q3W) plus IFN-α (30 μg BIW) or active surveillance until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was recurrence free survival (RFS). Secondary endpoints included overall survival (OS) and safety.
Results
From January 2021 to December 2021, TIS plus IFN-α group and active surveillance group enrolled 24 and 14 patients, respectively. Baseline characteristics were generally comparable between two groups, including MVI grade (M1: 90.0% vs 85.7%; M2: 10.0% vs 14.3%) and any tumours diameter > 5cm (65.0% vs 50.0%) in TIS plus IFN-α, respectively. At data cutoff (17 Apr 2023), RFS was not reached in TIS plus IFN-α group (95%CI: 9.8-NE), whereas in active surveillance group was 17.09 month (95%CI: 4.8-NE). 1-year RFS rate in TIS plus IFN-α and active surveillance group was 79.2% (95%CI: 0.5-0.9) and 50.0% (95%CI: 0.2-0.7), separately. Median OS was not reached in either group. No severe postoperative complications were observed. In TIS plus IFN-α group, Grade 1 or higher AEs were mainly rash (20.0%), pyrexia (15.0%), pruritus (10.0%) and diarrhea (10.0%).
Conclusions
These results suggested that HCC patients with MVI may benefit from adjuvant tislelizumab plus IFN-α, which can be tested in a future confirmatory trial. We will continue follow-up and update the data further. In the meantime, related basic experiments are underway.
Clinical trial identification
ChiCTR2000037461.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Shanghai Shenkang Hospital Development Center (No. SHDC2020CR3031B).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18